



(51) International Patent Classification:

C07K 16/46 (2006.01) C12N 15/13 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/JP2021/013460

(22) International Filing Date:

30 March 2021 (30.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2020-062326 31 March 2020 (31.03.2020) JP

(71) Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
[JP/JP]; 5-1, Ukima 5-chome, Kita-ku, Tokyo, 1158543
(JP).


(72) Inventors: NAOI, Sotaro; c/o CHUGAI SEIYAKU

KABUSHIKI KAISHA, 135, Komakado 1-chome, Gotemba-shi, Shizuoka, 4128513 (JP). FENG, Shu; c/o Chugai Pharmabody Research Pte. Ltd., 3, Biopolis Drive, #07-11 to 16 Synapse, 138623 (SG). IGAWA, Tomoyuki; c/o Chugai Pharmabody Research Pte. Ltd., 3, Biopolis Drive, #07-11 to 16 Synapse, 138623 (SG). HO, Shu Wen Samantha; c/o Chugai Pharmabody Research Pte. Ltd., 3, Biopolis Drive, #07-11 to 16 Synapse, 138623 (SG).

(74) Agent: HARUNA, Masao et al.; Kantetsu Tsukuba Bldg. 6F, 1-1-1, Oroshi-machi, Tsuchiura-shi, Ibaraki, 3000847 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

(54) Title: DLL3-TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF



(57) Abstract: The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxicity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*